Parametric Portfolio Associates LLC cut its holdings in shares of Humana Inc (NYSE:HUM) by 6.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 603,945 shares of the insurance provider’s stock after selling 38,365 shares during the quarter. Parametric Portfolio Associates LLC owned 0.45% of Humana worth $160,227,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of HUM. BlackRock Inc. increased its stake in shares of Humana by 1.6% in the 1st quarter. BlackRock Inc. now owns 12,190,049 shares of the insurance provider’s stock valued at $3,242,553,000 after purchasing an additional 186,997 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Humana by 8.3% in the 4th quarter. Geode Capital Management LLC now owns 1,773,576 shares of the insurance provider’s stock worth $507,198,000 after acquiring an additional 135,776 shares in the last quarter. Northern Trust Corp boosted its position in shares of Humana by 0.5% during the 1st quarter. Northern Trust Corp now owns 1,743,519 shares of the insurance provider’s stock valued at $463,775,000 after purchasing an additional 8,221 shares in the last quarter. Wells Fargo & Company MN grew its stake in Humana by 1.8% during the second quarter. Wells Fargo & Company MN now owns 1,367,476 shares of the insurance provider’s stock worth $362,790,000 after purchasing an additional 24,314 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Humana by 1.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,181,373 shares of the insurance provider’s stock worth $313,417,000 after buying an additional 21,207 shares in the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.
In other Humana news, insider Brian P. Leclaire sold 7,239 shares of Humana stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.54% of the stock is currently owned by company insiders.
HUM stock traded down $0.15 during midday trading on Wednesday, reaching $276.70. The stock had a trading volume of 50,868 shares, compared to its average volume of 877,683. Humana Inc has a 52-week low of $225.65 and a 52-week high of $355.88. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The company’s fifty day simple moving average is $287.24 and its 200 day simple moving average is $269.54. The company has a market cap of $37.24 billion, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 1.19 and a beta of 0.84.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 EPS for the quarter, beating the Zacks’ consensus estimate of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The business had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same period in the prior year, the business earned $3.96 earnings per share. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. Sell-side analysts predict that Humana Inc will post 17.63 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.80%. The ex-dividend date is Friday, September 27th. Humana’s payout ratio is currently 15.12%.
A number of analysts recently commented on HUM shares. JPMorgan Chase & Co. boosted their target price on Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Morgan Stanley increased their price target on Humana from $315.00 to $342.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. ValuEngine raised Humana from a “sell” rating to a “hold” rating in a research note on Friday, July 12th. Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $300.00 to $345.00 in a report on Monday, August 12th. Finally, Piper Jaffray Companies lifted their price target on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. Humana presently has an average rating of “Buy” and an average target price of $341.95.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: Dead Cat Bounce
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.